Tanju Yusuf Erdil

Tanju Yusuf Erdil

Auto-generated profile, based on publicly available information

Tanju Yusuf Erdil

Department of Nuclear Medicine, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
MAMustafa Aras
Mustafa Aras
TETanju Y. Erdil
Tanju Y. Erdil
FDFaysal Dane
Faysal Dane
SGSerkan Gungor
Serkan Gungor
TOTunc Ones
Tunc Ones
HTHalil T. Turoglu
Halil T. Turoglu
To compare response assessment according to the WHO, RECIST 1.1, EORTC, and PERCIST criteria in patients diagnosed with malignant solid tumors and who had received cytotoxic chemotherapy to establish the strength of agreement between each criterion. Sixty patients with malignant solid tumors were included in this retrospective study. The baseline and the sequential follow-up fluorine-18-fluorodeoxyglucose PET/computed tomography (CT) of each patient were evaluated according to the WHO, RECIST 1.1, EORTC, and PERCIST criteria. PET/CT images were used for both metabolic and anatomic evaluation. The concurrent diagnostic CT and MRI images (performed within 1 week of PET/CT) were also utilized when needed. The results were compared using the κ-statistics. The response and progression rates according to the WHO criteria were 37 and 38%, respectively. The same ratios were also found for RECIST 1.1 (κ=1). The response and progression rates according to the EORTC criteria were 47 and 40%, respectively. When PERCIST criteria were used, one patient with progressive disease was upgraded to stable disease (κ=0.976). As we found the same results with WHO and RECIST 1.1 criteria, we used WHO criteria to compare the anatomic and metabolic criteria. When we compared the WHO and EORTC criteria, there was an agreement in 80% of the patients (κ=0.711). With WHO and PERCIST criteria, there was an agreement in 81.6% of the patients (κ=0.736). Significant agreement was detected when the WHO, RECIST 1.1, EORTC, and PERCIST criteria were compared both within as well as between each other.

1 February 2021 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
SÖSalih Özgüven
Salih Özgüven
NFNuh Filizoğlu
Nuh Filizoğlu
SKSelin Kesim
Selin Kesim
KÖKevser Öksüzoğlu
Kevser Öksüzoğlu
FŞFeyza Şen
Feyza Şen
TETanju Yusuf Erdil
Tanju Yusuf Erdil
Somatostatin is an endocrine peptide hormone that regulates neurotransmission and cell proliferation by interacting with G protein-coupled somatostatin receptors (SSTRs). SSTRs are specific molecular targets of several radiotracers for neuroendocrine tumor (NET) imaging. Gallium-68 (68Ga)-DOTA-TATE is widely used for positron emission tomography/computed tomography (PET/CT) imaging of SSTRs and has shown a higher affinity for SSTR2, the most common SSTR subtype found in NETs. We aimed to analyze the distribution pattern of 68Ga-DOTA-TATE in normal subjects. A total of 617 consecutive 68Ga-DOTA-TATE PET/CT whole-body scans performed in our department from May 2015 through April 2020 with known or suspected neuroendocrine malignancies, mostly to evaluate adrenal adenomas, were retrospectively analyzed by 2 nuclear medicine physicians. One hundred eighteen subjects without a diagnosis of NET, with no tracer avid lesion of NET on 68Ga-DOTA-TATE PET/CT, and followed up for at least 6 months (average 2-3 years) without any biochemical, clinical, or imaging findings suggestive of NET were included in this study. The highest uptake of 68Ga-DOTA-TATE was noted in the spleen followed by the kidneys, adrenal glands, liver, stomach, small intestine, prostate gland, pancreas head, pancreas body, thyroid gland, and uterus, in descending order. Minimal to mild uptake was detected in the submandibular glands, parotid glands, thymus, muscles, bones, breast, lungs, and mediastinum. Our study shows the biodistribution pattern of 68Ga-DOTA-TATE in normal subjects and the ranges of the maximum standard uptake value (SUVmax) and SUVmean values of 68Ga-DOTA-TATE obtained in several tissues for reliably identifying malignancy in 68Ga-DOTA-TATE PET/CT studies.

29 May 2000 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
TETanju Yusuf Erdil
Tanju Yusuf Erdil
KÖKutlan Özker
Kutlan Özker
LKLevent Kabasakal
Levent Kabasakal
BKBedii Kanmaz
Bedii Kanmaz
KSKerim Sönmezoglu
Kerim Sönmezoglu
ÇÖÇetin Önsel
Çetin Önsel

1 February 2005 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
SISabahat Inanir
Sabahat Inanir
NBNese Biyikli
Nese Biyikli
ONOmid Noshari
Omid Noshari
BCBillur Caliskan
Billur Caliskan
HTHalil Tugtepe
Halil Tugtepe
HAHarika Alpay
Harika Alpay
Contradictory supranormal renal function (SRF) in unilateral hydronephrosis is a debatable subject resulting from the methodology of nuclear renography or the characteristics of the patient. In this study, we aimed to investigate the frequency and comparison of SRF with MAG-3 scans by 8 different technical analyses in pediatric hydronephrosis. We reviewed Tc-99m MAG-3 scans in 82 children with unilateral hydronephrosis (52 male, 30 female, mean age: 47.7 ± 64.5 months). Of 82, 34 also had Tc-99m DMSA scans. Data were reprocessed with 4 different regions of background activity (subrenal, perirenal C-type, perirenal ring, and lateral) at 2 different time intervals (1–2 and 2–3 minute), and 8 different estimates of MAG-3 differential renal function (DRF) were obtained in 67 patients. SRF was defined as DRF greater than 55% in the hydronephrotic kidney. The routine processing protocol showed only 3 renal units with SRF, and all were on the right side (3.6%). After reprocessing, a total of 10 dilated kidneys had SRF in 1 or more of DRF estimates (5.2% of all estimations). These cases were significantly younger (8.1 ± 6.7 vs. 42.5 ± 52.5, P < 0.05) and had a larger renal area ratio (1.25 ± .24 vs. 1.07 ± .21, P < 0.05). There was no SRF with DMSA. In comparison between MAG-3 and DMSA DRF in 20 children who underwent both tests within 3 months, the best correlation was obtained when C-type correction was used for both agents at 2 time intervals (r: .86 and .84 for early and late time intervals, P < 0.00001, respectively). SRF in unilateral hydronephrosis is, at least, in part, technical in origin in this particular pediatric patient population with tubular immaturity (ie, physiological high background activity) and asymmetric kidney size.

27 December 2012 in Iranian Journal of Radiology
Verified
Journal Article
Open access
PDF file
MAMustafa Aras
Mustafa Aras
TOTunc Ones
Tunc Ones
FDFaysal Dane
Faysal Dane
ONOmid Nosheri
Omid Nosheri
SISabahat Inanir
Sabahat Inanir
HTHalil Turgut Turoglu
Halil Turgut Turoglu
Fibrous dysplasia of the bone (FDB) is a common, genetic, developmental disorder with a benign course. FDB can be seen anywhere throughout the skeleton. It is usually asymptomatic and found incidentally on imaging studies that are performed for other purposes. Although whole body 18 F-flourodeoxyglucose PET/CT (FDG PET/CT) is widely used in tumor imaging, infections and benign pathologies like FDB may cause false positive results. Herein we report the case of a 48-year-old FDB patient with transitional cell carcinoma of the urinary bladder. Restaging FDG PET/CT showed multiple mild to moderate hypermetabolic bone lesions which were initially misinterpreted as bone metastases. In this case report, we aimed to guide physicians in evaluating bone lesions in cancer patients with FDB in the light of the literature. Keywords: Fibrous Dysplasia, Polyostotic; Bone and Bones; 18F-Flourodeoxyglucose, PET, CT

5 December 2013 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
MAMustafa Aras
Mustafa Aras
FDFuat Dede
Fuat Dede
TÖTunç Önes
Tunç Önes
SISabahat İnAnır
Sabahat İnAnır
TETanju Yusuf Erdil
Tanju Yusuf Erdil
HTHalil Turgut Turoğlu
Halil Turgut Turoğlu
Contrast-enhanced CT or MRI are used as a gold standard imaging modalities in the detection and characterization of renal masses. On the other hand, the role of FDG PET/CT in evaluating primary or metastatic cancers of the kidney is limited due to the excretion of FDG through urinary tract. We reported the FDG PET/CT of a lung cancer patient with multiple metastases in both kidneys which were missed in previous PET/CT, and underestimated on sequential diagnostic abdominal CT study. None declared.